HN2010000573A - Anticuerpos anti-il-12/23p40, epitopes, formulaciones, composiciones, metodos y usos - Google Patents

Anticuerpos anti-il-12/23p40, epitopes, formulaciones, composiciones, metodos y usos

Info

Publication number
HN2010000573A
HN2010000573A HN2010000573A HN2010000573A HN2010000573A HN 2010000573 A HN2010000573 A HN 2010000573A HN 2010000573 A HN2010000573 A HN 2010000573A HN 2010000573 A HN2010000573 A HN 2010000573A HN 2010000573 A HN2010000573 A HN 2010000573A
Authority
HN
Honduras
Prior art keywords
methods
compositions
epithopes
formulations
bodies
Prior art date
Application number
HN2010000573A
Other languages
English (en)
Inventor
Dal Monte Paul
Giles-Komar Jill
Heavner George
Knight David
Khossravi Mehrnaz
Luo Jeffrey
Shealy David
Volkin David
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of HN2010000573A publication Critical patent/HN2010000573A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRESENTE INVENCION A UN ANTICUERPO ANTI-IL-12/23P40 QUE SE UNE A UNA PORCION DE LA PROTEINA IL-12 O IL-23 QUE CORRESPONDE A LA SUBUNIDAD P40 DE IL-12 O IL-23, QUE INCLUYEN COMPOSICIONES, FORMULAS Y METODOS DE ADMINISTRACION CON APLICACIONES EN DIAGNOSTICO Y/O USOS Y DISPOSITIVOS TERAPEUTICOS.
HN2010000573A 2007-09-28 2010-03-26 Anticuerpos anti-il-12/23p40, epitopes, formulaciones, composiciones, metodos y usos HN2010000573A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97599707P 2007-09-28 2007-09-28

Publications (1)

Publication Number Publication Date
HN2010000573A true HN2010000573A (es) 2012-12-10

Family

ID=40850818

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2010000573A HN2010000573A (es) 2007-09-28 2010-03-26 Anticuerpos anti-il-12/23p40, epitopes, formulaciones, composiciones, metodos y usos

Country Status (9)

Country Link
US (1) US20090181027A1 (es)
EP (1) EP2205276A4 (es)
CR (1) CR11399A (es)
EC (1) ECSP10010056A (es)
GT (1) GT201000073A (es)
HN (1) HN2010000573A (es)
NI (1) NI201000042A (es)
SV (1) SV2010003517A (es)
WO (1) WO2009114040A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012094623A2 (en) * 2011-01-07 2012-07-12 Abbott Laboratories Anti-il-12/il-23 antibodies and uses thereof
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
KR20240046648A (ko) * 2016-09-30 2024-04-09 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법
WO2018181876A1 (ja) 2017-03-31 2018-10-04 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 水性製剤及び注射器入り水性製剤、並びに、抗体タンパク脱凝集剤及び抗体タンパク脱凝集方法
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019106206A1 (en) * 2017-12-01 2019-06-06 Fyb 202 Project Gmbh Stable, low viscosity, high concentration liquid formulations of an anti-il-12/23p40 antibody
US11578124B2 (en) 2018-05-18 2023-02-14 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-IL12/IL23 antibody
FI3883606T3 (fi) * 2018-09-24 2023-09-07 Janssen Biotech Inc Turvallinen ja tehokas menetelmä haavaisen paksusuolitulehduksen hoitamiseksi anti-il12/il23-vasta-aineella
BR112021009287A2 (pt) 2018-11-20 2021-10-26 Janssen Biotech, Inc. Método seguro e eficaz para tratar psoríase com anticorpo específico anti-il-23
JP2022534020A (ja) 2019-05-23 2022-07-27 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
WO2021018114A1 (zh) * 2019-07-30 2021-02-04 中山康方生物医药有限公司 抗人p40蛋白域抗体及其用途
KR20220141847A (ko) * 2020-02-14 2022-10-20 얀센 바이오테크 인코포레이티드 항-il12/il23 항체로 궤양성 결장염을 치료하는 안전하고 효과적인 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
CA2796140A1 (en) * 1999-03-25 2000-09-28 Jochen Salfeld Human antibodies that bind human il-12 and methods for producing
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
JP5485489B2 (ja) * 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
CA2591813A1 (en) * 2004-12-21 2006-06-29 Centocor, Inc. Anti-il-12 antibodies, epitopes, compositions, methods and uses
NZ560844A (en) * 2005-03-08 2008-08-29 Pharmacia & Upjohn Co Llc Anti-MAdCAM antibody compositions
NZ564098A (en) * 2005-06-15 2010-04-30 Schering Corp Anti-IGF1R antibody formulations
CA2613512A1 (en) * 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
WO2007074880A1 (ja) * 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤

Also Published As

Publication number Publication date
CR11399A (es) 2010-08-18
EP2205276A2 (en) 2010-07-14
EP2205276A4 (en) 2012-08-15
SV2010003517A (es) 2010-08-10
US20090181027A1 (en) 2009-07-16
WO2009114040A2 (en) 2009-09-17
WO2009114040A3 (en) 2010-05-27
GT201000073A (es) 2012-04-19
NI201000042A (es) 2010-09-13
ECSP10010056A (es) 2010-04-30

Similar Documents

Publication Publication Date Title
HN2010000573A (es) Anticuerpos anti-il-12/23p40, epitopes, formulaciones, composiciones, metodos y usos
EA200870129A1 (ru) Человеческие антитела против il-23, композиции, способы и применение
AR060130A1 (es) Formulacion de un anticuerpo monoclonal humano anti- igf-1r
ECSP077261A (es) Composición de anticuerpo her2
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
AR051484A1 (es) Moleculas de anticuerpo que tienen especificidad para la il - 17 humana
HN2006016512A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
CR20160203A (es) Inhibidores de tirosina cinasa de bruton
UA118441C2 (uk) Антитіло, що розпізнає альфа-синуклеїн
CY1116842T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
BR112015023391A2 (pt) formulações compreendendo conjugado droga-anticorpo anti-egfr
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
CR10561A (es) Vacunas para malaria
CL2008003537A1 (es) Compuestos derivados de 2-amino-pirimidina, antagonistas de receptores h4; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad alergica, inmunologica o inflamatoria o dolor.
CL2008002885A1 (es) Anticuerpo anti-receptor de interleucina-6 (il-6); y composicion farmaceutica que lo comprende
EA201100694A1 (ru) Антитело к cd38 человека и его применение
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
MX2009005414A (es) Formulaciones liquidas de anticuerpo antirrabico.
ATE552276T1 (de) Modifizierter anti-cd52-antikörper
CR20160041A (es) Proteína de fusión terapéutica
TR201802380T4 (tr) Benzonaftiridin içeren aşılar.
BR112015018270A2 (pt) composições que compreendem 15-ohepa e métodos de uso das mesmas
PE20081687A1 (es) Proteina de fusion